ASGT Annual Meeting


		Attendee Information ASGT Fourth Annual Meeting May 30-June 3, 2001, Seattle, Washington

Meeting Information \| Program at a Glance \| Preliminary Program Schedule Exhibitors and Supporters \| Home

Preliminary Program Schedule

Wednesday, May 30
Thursday, May 31
Friday, June 1
Saturday, June 2
Sunday, June 3

Plenary Session II 8:00 a.m. – 9:00 a.m.
	Keynote Speaker: Don C. Wiley, PhD
Break 9:00 a.m. – 9:30 a.m.
Presidential Symposium 9:30 a.m. – 12:00 p.m.
	Awards Outstanding Contribution: Alain Fischer
	Presidential lecture:
		John Gurdon – Stem Cells Mark Groudine – Transcription Jeffrey Bluestone – Immunity

Meet the Professor Lunches (ticketed session) 12:15 p.m. – 1:15 p.m.
		W. French Anderson, MD – In Utero Gene Therapy Helen Blau, PhD – Stem Cells in Gene Therapy Malcolm Brenner, MD – Clinical Trials/Regulatory Affairs Beverly L. Davidson, PhD – Developing Vectors Gene for Delivery to the Brain Fred Gage, PhD – Neurobiology Joseph Glorioso, PhD – Herpes virus vectors Katherine High, MD – Gene Transfer for Hemophilia Dusty Miller, PhD – Should there be Limits to the Use of Components From Pathogenic Viruses in Gene therapy vectors? Richard Mulligan, PhD – New Strategies and Technologies for Gene Therapy

Simultaneous Oral Abstract Sessions 1:30 p.m. – 4:00 p.m.

Workshops 1:30 p.m. – 4:00 p.m.
	Workshop 6: Lentiviral Vectors Moderators: Luigi Naldini, Susan Kingsman Speakers:
		Garry Nolan – Lentiviruses: Delivery and delivered Jakob Reiser – HIV 1-based lentiviral vectors: Tools for gene delivery and gene discovery Didier Trono – Lentivirus genevasion: from mechanistic exploration to finalistic exploitation Tal Kafri – Safe production of lentivirus vectors Susan Kingsman – Lentivectors for the analysis and treatment of neurodegenerative diseases Luigi Naldini – Lentiviral vectors: Performance in experimental gene transfer and potential for gene therapy

	Workshop 7: Adenoviral Vectors Moderators: Stefan Kochanak, Jeffrey Chamberlain Speakers:
		Art Beaudet – Progress with helper-dependent adenoviral vectors Wei-Wei Zhang – Pre-clinical efficacy and safety studies of MiniAdFVIII for treatment of hemophilia A Tom Wickham – Progress towards genetically retargeting adenoviral vectors Stefan Kochanak – "Gutless" adenoviral vectors: vector development, production and applications Jeffrey Chamberlain – Efficacy of gutted adenoviral vectors in normal and diseased muscle Dinko Valerio – Improved adenoviral vectors for gene therapy and vaccines

	Workshop 8: Novel Technologies Moderator: David Russell Speakers:
		John Rossi – Novel intracellular localization strategies for anti-HIV RNA therapeutic agents Perry Hackett – The "Sleeping Beauty" transposon system for gene delivery and expression into mammalian chromosomes David Russell – Homologous gene targeting by AAV vectors Michele Calos – Site-specific genomic integration Chris Contag – Developing in vivo measurements of gene transfer Yen Choo – Designer zinc finger transcription factors for specific gene regulation

	Workshop 9: Non-Viral Vectors II Moderator: Jean-Paul Behr Speakers:
		Cyrus Safinya – DNA-lipid complexes and interactions with cells: supramolecular assembly and gene delivery Sun Won Kim – Tailor-made polymeric carriers for delivery of therapeutic plasmid DNA Alexander Kabanov – Polyplex-based gene delivery systems: current state and major impediments Yasufumi Kaneda – The device for the enhancement of transgene expression and its use for cancer gene therapy Jean-Paul Behr – Dimerizable cationic detergents

	Workshop 10: Fanconi Anemia Moderators: Marcus Grompe, Odille Cohen-Haguenauer Speakers:
		Alan D’Andrea – Interaction of the Fanconi Anemia proteins in a common pathway Grover Bagby – Molecular pathogenesis of bone marrow failure in Fanconi Anemia Francesco Galimi – Gene therapy of Fanconi Anemia by lentiviral vectors Christopher Walsh – Fanconi Anemia: a model disorder for stem cell gene transfer Odille Cohen-Haguenauer – Selective growth advantage and functional correction of FA-A patients primary BM: comparing retrovirus SV40 and lentiviral vectors Marcus Grompe – Murine models of Fanconi anemia: pathophysiology and treatment

	Workshop 11: DNA Vaccines Moderator: Margaret Liu Speakers:
		Harriet Robinson – DNA priming and recombinant pox virus boosters, real progress towards an HIV vaccine Jeffrey Ulmer – DNA delivery technologies Larry Steinman – Suppressive DNA vaccination for tolerance to autoimmune disease John Gutheil – Safety profile of plasmid DNA based therapy of cancer

Exhibits Open 4:00 p.m. – 7:00 p.m.

Business Meeting 4:15 p.m. – 5:00 p.m.

Poster Sessions 4:30 p.m. – 7:00 p.m.

Corporate Symposia 7:00 p.m. – 10:00 p.m.
	Targeted Genetics – Biology of Gene Delivery Barrie J. Carter, PhD, Session Chair Room 606-609 Understanding the biology of gene delivery systems is crucial to developing the most efficient and specific systems suited for individual disease applications. Increased insights into the entry and trafficking of gene delivery systems and the fate of the delivered genome in the target cell nucleus enables two approaches to developing appropriate delivery systems for individual applications. First, understanding more clearly the biology of currently available systems permits a more judicious choice of applications. Second, this also forms the basis for development of advanced delivery systems with increased efficiency, stability and targeting specificity. General concepts of understanding trafficking pathways of gene delivery systems, how to modify or enhance these and how to obtain targeting via direct delivery or by modifying structure of gene delivery systems will be discussed by several speakers using a viral system, AAV, and synthetic delivery system as examples.

	Avigen – AAV Vectors in Clinical and Preclinical Research Alan McClelland, PhD, Session Chair Room 611-614 Vectors derived from AAV show promise in a number of animal model systems where efficient gene transfer, long term gene expression and a lack of toxicity have been observed. As a result there is considerable interest in the clinical evaluation of AAV vectors, although at present only a small number of clinical trials are underway. This symposium will highlight recent developments in the clinical investigation of AAV vectors, and preclinical studies with AAV vectors which may provide a basis for clinical trials in the near future.

		Program schedule for Saturday >